Periprocedural Management of the Patient With Diabetes Mellitus Undergoing Coronary Angiography: Current Practice

Abstract

Despite advances in procedural technique and pharmacotherapy, diabetic patients experience worse outcomes than nondiabetic patients undergoing percutaneous coronary intervention (PCI).1 Periprocedural hyperglycemia is associated with adverse clinical outcomes in patients undergoing PCI,2–5 and studies have suggested that treating periprocedural hyperglycemia may improve outcomes by attenuating glucose-mediated ischemic injury at the time of PCI.6–7 Simple preventive strategies such as continuing long-acting hypoglycemic medications have not been evaluated and there are no guidelines for periprocedural use of these medications. We conducted an anonymous electronic survey of cardiologists referring patients for coronary angiography using the American Heart Association Cardiology Fellows Society of Greater New York and the Society of Cardiovascular Angiography and Interventions from March through July 2011. Of the 144 survey responders, 24% are fellows-in-training and 33% are faculty at a medical school. Among this cohort, 60% believe hyperglycemia at the time of PCI is harmful, and 94% believe hypoglycemia at the time of PCI is harmful. While a majority of clinicians routinely hold oral hypoglycemic medications prior to angiography, substantial numbers do not, with nearly half routinely continuing thiazolidinediones on the morning of coronary angiography (see Table). Clinicians are more likely to continue insulin based regimens than oral medications, but again there is no uniformity of practice. In patients with uncontrolled diabetes mellitus (glycosylated hemoglobin >10% or blood glucose levels >200mg/dL), a little more than one-third of physicians reported they would change their usual practice and continue hypoglycemic medications prior to coronary angiography. Table Percent of survey responders who report routinely holding hypoglycemic medications prior to procedure in diabetic patients referred for coronary angiography (Percent of those who routinely hold but will continue medication in uncontrolled diabetes mellitus, ... The risk of hypoglycemia appears to be a major factor preventing physicians from continuing long-acting hypoglycemic medications prior to PCI. Delays in scheduled cardiac catheterization procedures frequently occur, and therefore, there is uncertainty regarding how long a patient will be fasting prior to their coronary angiogram. However, hypoglycemia is not likely to complicate routine coronary angiography since patients with a late afternoon scheduled procedure are usually given permission to have a light breakfast and to eat relatively soon after the procedure is completed even when conscious sedation is administered. Furthermore there is substantial variability in eating patterns and stress levels on the day of PCI, which may lead to hyperglycemia at the time of arterial access. This may explain why the majority of physicians report continuing at least half the dose of long-acting insulin in all diabetic patients prior to angiography. Our data suggest that physicians are influenced by the pharmacologic properties of the various hypoglycemic agents when designing management strategies for diabetic patients undergoing coronary angiography. For example, thiazolidinediones and glargine-insulin are unlikely to cause sudden hypoglycemia in the setting of variable eating patterns. Physicians are, therefore, less likely to hold thiazolidinediones compared to sulfonylureas prior to cardiac catheterization. Similarly, physicians are more likely to continue full dose glargine-insulin than NPH-insulin on the day of coronary angiography. Thus it is concerning that the management of patients treated with metformin reflects a lack of knowledge of the pharmacologic properties of this drug. Metformin is contraindicated in patients with chronic kidney disease due to the risk of lactic acidosis at very high metformin concentrations. However, in patients with normal kidney function, renal function is unlikely to change following angiography unless contrast-induced nephropathy develops, a complication that occurs 48 to 72 hours after contrast exposure. The half-life of metformin is between 2 to 5 hours, and, therefore, the drug label instructs patients to stop the medication for 48 hours after contrast exposure. Nevertheless, 88% of physicians in the current survey report holding metformin prior to coronary angiography. Furthermore, of these physicians, 28% report holding metformin for both 2 days before and 2 days after coronary angiography. Although the response rate to this survey was low, and we have no data on non-responders, we obtained a sample of physicians at various stages of practice, including fellows-in-training and attending physicians, in both private practice and academics. Survey responders may also have self-selecting features. For example, only those who believe this is an important topic of discussion may have responded to the survey. However, we still demonstrate clinical equipoise in the management of hypoglycemic medications in the diabetic patient undergoing coronary angiography. We conclude there is considerable variability in the management of hypoglycemic medications by cardiologists sending patients for coronary angiography. An evidence base to better establish optimal goals for glycemic control in the setting of PCI and education of physicians to avoid premature discontinuation of diabetes therapies is needed. Furthermore, prospective randomized studies are warranted to determine if continuing long-acting hypoglycemic medications prior to PCI is safe and has a beneficial effect on long-term clinical outcomes.